191 related articles for article (PubMed ID: 37215108)
1. TCR T cells overexpressing c-Jun have better functionality with improved tumor infiltration and persistence in hepatocellular carcinoma.
Hussein MS; Li Q; Mao R; Peng Y; He Y
Front Immunol; 2023; 14():1114770. PubMed ID: 37215108
[TBL] [Abstract][Full Text] [Related]
2. Identification of α-fetoprotein-specific T-cell receptors for hepatocellular carcinoma immunotherapy.
Zhu W; Peng Y; Wang L; Hong Y; Jiang X; Li Q; Liu H; Huang L; Wu J; Celis E; Merchen T; Kruse E; He Y
Hepatology; 2018 Aug; 68(2):574-589. PubMed ID: 29443377
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Studies of the Off-Target Reactivity of AFP
Cai L; Caraballo Galva LD; Peng Y; Luo X; Zhu W; Yao Y; Ji Y; He Y
Front Immunol; 2020; 11():607. PubMed ID: 32395117
[TBL] [Abstract][Full Text] [Related]
4. Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma.
Sun L; Guo H; Jiang R; Lu L; Liu T; He X
Tumour Biol; 2016 Jan; 37(1):799-806. PubMed ID: 26250457
[TBL] [Abstract][Full Text] [Related]
5. Selection of a Clinical Lead TCR Targeting Alpha-Fetoprotein-Positive Liver Cancer Based on a Balance of Risk and Benefit.
Luo X; Cui H; Cai L; Zhu W; Yang WC; Patrick M; Zhu S; Huang J; Yao X; Yao Y; He Y; Ji Y
Front Immunol; 2020; 11():623. PubMed ID: 32425926
[TBL] [Abstract][Full Text] [Related]
6. Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer.
Docta RY; Ferronha T; Sanderson JP; Weissensteiner T; Pope GR; Bennett AD; Pumphrey NJ; Ferjentsik Z; Quinn LL; Wiedermann GE; Anderson VE; Saini M; Maroto M; Norry E; Gerry AB
Hepatology; 2019 May; 69(5):2061-2075. PubMed ID: 30561769
[TBL] [Abstract][Full Text] [Related]
7. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U
Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074
[TBL] [Abstract][Full Text] [Related]
8. Use of Expression Profiles of HBV-DNA Integrated Into Genomes of Hepatocellular Carcinoma Cells to Select T Cells for Immunotherapy.
Tan AT; Yang N; Lee Krishnamoorthy T; Oei V; Chua A; Zhao X; Tan HS; Chia A; Le Bert N; Low D; Tan HK; Kumar R; Irani FG; Ho ZZ; Zhang Q; Guccione E; Wai LE; Koh S; Hwang W; Chow WC; Bertoletti A
Gastroenterology; 2019 May; 156(6):1862-1876.e9. PubMed ID: 30711630
[TBL] [Abstract][Full Text] [Related]
9. Targeting Alpha-Fetoprotein (AFP)-MHC Complex with CAR T-Cell Therapy for Liver Cancer.
Liu H; Xu Y; Xiang J; Long L; Green S; Yang Z; Zimdahl B; Lu J; Cheng N; Horan LH; Liu B; Yan S; Wang P; Diaz J; Jin L; Nakano Y; Morales JF; Zhang P; Liu LX; Staley BK; Priceman SJ; Brown CE; Forman SJ; Chan VW; Liu C
Clin Cancer Res; 2017 Jan; 23(2):478-488. PubMed ID: 27535982
[TBL] [Abstract][Full Text] [Related]
10. Identification of an HLA-A*24:02-restricted α-fetoprotein signal peptide-derived antigen and its specific T-cell receptor for T-cell immunotherapy.
Li Z; Gong H; Liu Q; Wu W; Cheng J; Mei Y; Chen Y; Zheng H; Yu X; Zhong S; Li Y
Immunology; 2020 Apr; 159(4):384-392. PubMed ID: 31849039
[TBL] [Abstract][Full Text] [Related]
11. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
12. A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma.
Zhu W; Zhang Z; Chen J; Chen X; Huang L; Zhang X; Huang X; Ma N; Xu W; Yi X; Lu X; Fu X; Li S; Mo G; Wang Y; Yuan G; Zang M; Li Q; Jiang X; He Y; Wu S; He Y; Li Y; Hou J
Signal Transduct Target Ther; 2024 Apr; 9(1):101. PubMed ID: 38643203
[TBL] [Abstract][Full Text] [Related]
13. Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma.
Chen A; Yu Z; Ma N; Lu X; Zhang Y; Xu W; Wang Y; Xie J; Qin Y; Mo G; Wu S; Hou J; Zhu W
Cancer Immunol Immunother; 2024 Feb; 73(3):49. PubMed ID: 38349553
[TBL] [Abstract][Full Text] [Related]
14. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
15. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1
Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742
[TBL] [Abstract][Full Text] [Related]
16. TCR gene-modified T cells can efficiently treat established hepatitis C-associated hepatocellular carcinoma tumors.
Spear TT; Callender GG; Roszkowski JJ; Moxley KM; Simms PE; Foley KC; Murray DC; Scurti GM; Li M; Thomas JT; Langerman A; Garrett-Mayer E; Zhang Y; Nishimura MI
Cancer Immunol Immunother; 2016 Mar; 65(3):293-304. PubMed ID: 26842125
[TBL] [Abstract][Full Text] [Related]
17. Identification of Vβ7.1_H3F7 as a therapeutic gene encoding TCR specific to hepatocellular carcinoma.
Huang S; Shen H; Li Z; Chiu SK; Ruan R; Xiao L; Tzeng CM
Curr Gene Ther; 2014; 14(5):389-99. PubMed ID: 25174578
[TBL] [Abstract][Full Text] [Related]
18. In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma.
Liu Q; Tian Y; Li Y; Zhang W; Cai W; Liu Y; Ren Y; Liang Z; Zhou P; Zhang Y; Bao Y; Li Y
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33323464
[TBL] [Abstract][Full Text] [Related]
19. Cell-specific expression of artificial microRNAs targeting essential genes exhibit potent antitumor effect on hepatocellular carcinoma cells.
Mao C; Liu H; Chen P; Ye J; Teng L; Jia Z; Cao J
Oncotarget; 2015 Mar; 6(8):5707-19. PubMed ID: 25691059
[TBL] [Abstract][Full Text] [Related]
20. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
